Human clinical trials in androgenetic alopecia patients have reported modest improvements in hair density (10-20% increases) and hair shaft diameter (5-15% increases) following 6-12 months of daily topical GHK-Cu application, though results generally remain inferior to established treatments including minoxidil or finasteride
Lilly has said they plan to submit the drug to the FDA for type 2 diabetes approval sometime in 2026
Biotech Peptides makes no representations regarding therapeutic, cosmetic, or nutritional efficacy, and no statements about Pal-GHK-Cu should be interpreted as medical advice
The patented DAOgest enzyme supports healthy histamine levels in the small intestines, colon, uterus, bladder, prostate, placenta, and breast milk
Min Chu: nothing to disclose